Roche Holding (RHHBY)
(Delayed Data from OTC)
$40.18 USD
+0.35 (0.88%)
Updated Aug 9, 2024 04:00 PM ET
1-Strong Buy of 5 1
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
RHHBY 40.18 +0.35(0.88%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RHHBY
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
The Market's Excessive Recession Fears
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent
Other News for RHHBY
Biotech Alert: Searches spiking for these stocks today
Maintaining Sell Rating on Roche Holding AG Amid Limited Upside Potential
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Monte Rosa Therapeutics achieves milestones under Roche collaboration agreement
Disney, Airbnb dip despite quarterly beats: Morning Buzz